Strides Pharma Science Ltd
NSE:STAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Strides Pharma Science Ltd
NSE:STAR
|
IN |
|
Azucar Minerals Ltd
XTSX:AMZ
|
CA |
|
J
|
Jindal Stainless Ltd
BSE:532508
|
IN |
|
IMCD NV
AEX:IMCD
|
NL |
|
C
|
Challenger Exploration Ltd
ASX:CEL
|
AU |
|
F
|
Factset Research Systems Inc
SWB:FA1
|
US |
|
McCormick & Company Inc
NYSE:MKC
|
US |
|
Empresa Distribuidora y Comercializadora Norte SA
NYSE:EDN
|
AR |
|
W
|
Walmart Inc
XHAM:WMT
|
US |
|
Joint Corp
NASDAQ:JYNT
|
US |
|
Grab Holdings Ltd
NASDAQ:GRAB
|
SG |
|
Warner Music Group Corp
NASDAQ:WMG
|
US |
|
OpGen Inc
NASDAQ:OPGN
|
US |
|
HSBC Holdings PLC
LSE:HSBA
|
UK |
|
Triboo SpA
MIL:TB
|
IT |
|
M
|
Marley Spoon Group SE
XBER:MS1
|
LU |
|
S
|
Steakholder Foods Ltd
NASDAQ:STKH
|
IL |
|
F
|
Figma Inc
NYSE:FIG
|
US |
|
A
|
American Airlines Group Inc
F:A1G
|
US |
|
J
|
Jeisys Medical Inc
KOSDAQ:287410
|
KR |
|
Prime Focus Ltd
NSE:PFOCUS
|
IN |
|
H
|
Heidelberger Druckmaschinen AG
OTC:HBGRF
|
DE |
|
Fidelity National Financial Inc
NYSE:FNF
|
US |
|
Himax Technologies Inc
NASDAQ:HIMX
|
TW |
Wall St Price Targets
STAR Price Targets Summary
Strides Pharma Science Ltd
According to Wall Street analysts, the average 1-year price target for STAR is 1 438.2 INR with a low forecast of 1 424.1 INR and a high forecast of 1 480.5 INR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is STAR's stock price target?
Price Target
1 438.2
INR
According to Wall Street analysts, the average 1-year price target for STAR is 1 438.2 INR with a low forecast of 1 424.1 INR and a high forecast of 1 480.5 INR.
What is the Revenue forecast for Strides Pharma Science Ltd?
Projected CAGR
15%
Over the last 13 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 3 years is 15%.
What is the Operating Income forecast for Strides Pharma Science Ltd?
Projected CAGR
34%
Over the last 13 years, the compound annual growth rate for Operating Income has been 3%. The projected CAGR for the next 2 years is 34%.
What is the Net Income forecast for Strides Pharma Science Ltd?
Projected CAGR
-36%
Over the last 13 years, the compound annual growth rate for Net Income has been 24%. The projected CAGR for the next 3 years is -36%.
